Article in Japanese
Study of the clinical efficacy of cefmetazole for community-acquired pediatric urinary tract infection
Shintaro FUNAKI1), Keita MATSUBARA1), Tomoki SATO1), Hiroyuki SHIMOZONO1), Rika OKANO1)
Community-acquired urinary tract infection (UTI) in children has been treated with third-generation cephem, but now the use of broad-spectrum antibacterials is not recommended because they induce resistant bacteria, for example extended-spectrum β-lactamase (ESBL)-producing bacteria. Actually ESBL-producing bacteria is increasing even in community-acquired UTI. This study compared the efficacy of cefotaxime (CTX) and cefmetazole (CMZ) for UTI, retrospectively. The subjects consisted of 189 patients, who were admitted to this hospital with UTI from January 2016 to December 2019. Escherichia coli was the main pathogen recovered from 168 patients, 34 of which produced ESBL. There was no significant difference between the CMZ (n=144) and CTX administration group (n=45) regarding the background of the patients and the causative bacteria. Children with UTI caused by ESBL-producing bacteria, had an effective rate of 92.6% or 25/27 in the CMZ group, which was significantly higher than that in the CTX group (57.1%, 4/7) (p=0.048). It was suggested that CMZ can be used as one of the first-line drugs for community-acquired pediatric UTI, except for severe cases.
|Key words||urinary tract infection, extended-spectrum β-lactamase-producing bacteria, empiric therapy, cefmetazole, cefotaxime|
|Received||May 19, 2020|
|Accepted||November 30, 2020|